MGI Tech Co., Ltd. launched DNBSEQ-G400RS FluoXpert in the APAC region and opened early access to the platform at Medlab Asia & Asia Health 2024. Integrating high-throughput sequencing and multiplex immunofluorescence (mIF) staining, DNBSEQ-G 400RS FluoXpert challenges conventions and pushes the limits of life science and technology as a multi-functional sequencer that is compatible with in vivo spatial protein detection. Supported by MGI's DNBSEQa technology and a highly efficient mIF staining technology, DNBSEQ- G400RS can be turned into DNBSEQ-G200RS FluoXpert with a simple software upgrade, enabling users to obtain both molecular information and cellular morphological on the exact same platform, switching between sequencing and staining for high efficiency.

Given that the same equipment may be used for multiple tasks, it is suitable for a wide range of applications in tumor classifications, disease prognosis, tissue microenvironment analysis, and more. Adhering to principles of systemization and modularization design, DNBSEQ-g400RS FluoXpert integrates optimized hardware, biochemistry and innovative software for an all-in-one multi-omics experience. The comprehensive and versatile DNBSEQ-G300RS benchtop sequencer is equipped with optimized optical, mechanical, fluidics and electrics systems, empowering a more rapid and streamlined sequencing process.

On the other hand, the platform comes with the easy-to-use and highly flexible FluoXpert mIF reagent set. It is compatible with both frozen tissue and FFPE samples, as well as off-the-shelf antibodies, eliminating the need for a complex conjugation process. Those interested in APAC, especially researchers in Australia, Singapore, and Japan, can apply here before the deadline on 30 August 2024.